Skip to main content
GeneralHomeInvestorsNewsUzedy

Phase 3 data of mdc-IRM, first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia: – Prolonged time to impending relapse – Decreased risk of relapse – Increased chance of clinical stability

By November 1, 2021March 15th, 2024No Comments1 min read